Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glioblastoma mutliforme

Bristol-Myers Squibb (BMS) building

BMS to publish full clinical study reports in transparency drive

Partners with Duke University to grant access back to 2008

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

Bristol-Myers Squibb (BMS) building

BMS buys Alzheimer’s player iPierian in $725m deal

Takes control of several promising candidates for neurodegenerative diseases

- PMLiVE

FDA approves new indication for Pfizer/BMS’ Eliquis

Oral anticoagulant gains US approval for deep vein thrombosis use

Interview: Christopher Boulton, AstraZeneca

AstraZeneca’s director of UK marketing and medicines access on the company's increased focused on diabetes

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

Bristol-Myers Squibb (BMS) building

BMS shares fall on nivolumab jitters despite solid Q4 results

Awaiting data from ongoing studies before advancing cancer prospect

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

german flag

BMS and AZ pull diabetes drug in Germany

Unable to agree price with health authorities

- PMLiVE

BMS appoints leading oncologist to board

Thomas Lynch is director of Yale Cancer Center

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links